Vaxart, Inc. (VXRT)
OTCMKTS · Delayed Price · Currency is USD
0.7400
-0.0300 (-3.90%)
Mar 12, 2026, 3:59 PM EST
Vaxart Employees
Vaxart had 105 employees as of December 31, 2024. The number of employees decreased by 4 or -3.67% compared to the previous year.
Employees
105
Change (1Y)
-4
Growth (1Y)
-3.67%
Revenue / Employee
$2,259,600
Profits / Employee
$155,495
Market Cap
176.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 105 | -4 | -3.67% |
| Dec 31, 2023 | 109 | -55 | -33.54% |
| Dec 31, 2022 | 164 | 54 | 49.09% |
| Dec 31, 2021 | 110 | 82 | 292.86% |
| Dec 31, 2020 | 28 | 14 | 100.00% |
| Sep 30, 2020 | 30 | 2 | 7.14% |
| Jun 30, 2020 | 16 | -17 | -51.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Harvard Apparatus Regenerative Technology | 8 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Vaxart News
- 22 hours ago - Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Vaxart to Host Upcoming Conference Calls - GlobeNewsWire
- 2 months ago - Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 - GlobeNewsWire
- 4 months ago - Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript - Seeking Alpha
- 4 months ago - Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program - PRNewsWire
- 4 months ago - Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program - PRNewsWire
- 5 months ago - Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 - GlobeNewsWire